Accessibility Menu
 
DiaMedica Therapeutics logo

DiaMedica Therapeutics

(NASDAQ) DMAC

Current Price$6.47
Market Cap$349.16M
Since IPO (2012)-81%
5 Year-33%
1 Year+64%
1 Month-16%

DiaMedica Therapeutics Financials at a Glance

Market Cap

$349.16M

Revenue (TTM)

$0.00

Net Income (TTM)

$32.77M

EPS (TTM)

$-0.70

P/E Ratio

-9.28

Dividend

$0.00

Beta (Volatility)

0.85 (Low)

Price

$6.47

Volume

4,705

Open

$6.40

Previous Close

$6.47

Daily Range

$6.25 - $6.50

52-Week Range

$3.19 - $10.42

DMAC News

DMAC: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About DiaMedica Therapeutics

Industry

Biotechnology

Employees

35

CEO

Rick John Pauls, MBA

Headquarters

Minneapolis, MN 55447, US

DMAC Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-68%

Return on Capital

-61%

Return on Assets

-53%

Earnings Yield

-10.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$349.16M

Shares Outstanding

53.88M

Volume

4.71K

Short Interest

0.00%

Avg. Volume

221.62K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$34.40M

EBITDA

$34.35M

Operating Cash Flow

$29.06M

Capital Expenditure

$40.00K

Free Cash Flow

$29.10M

Cash & ST Invst.

$59.89M

Total Debt

$240.00K

DiaMedica Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$14.00K

-27.3%

Gross Margin

0.00%

N/A

Market Cap

$349.16M

N/A

Market Cap/Employee

$12.93M

N/A

Employees

27

N/A

Net Income

$8.74M

-10.6%

EBITDA

$9.62M

-22.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$59.65M

+36.2%

Accounts Receivable

$258.00K

+9.3%

Inventory

$0.00

N/A

Long Term Debt

$128.00K

-46.0%

Short Term Debt

$112.00K

+8.7%

Return on Assets

-53.39%

N/A

Return on Invested Capital

-61.16%

N/A

Free Cash Flow

$7.77M

-20.6%

Operating Cash Flow

$7.76M

-20.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENGNenGene Holdings Inc.
$6.69-1.04%
ALTAltimmune, Inc.
$3.34+7.05%
DBVTDBV Technologies S.A.
$21.06+2.73%
GALTGalectin Therapeutics Inc.
$2.67-0.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.31-0.02%

Questions About DMAC

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.